[Articles] Use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children: a randomised, placebo-controlled trial

Phase 3negativeOM-85Negative

AI Analysis

Summary

A randomized, placebo-controlled Phase 3 trial found that oral OM-85 bacterial lysate did not reduce the incidence of wheezing lower respiratory tract illness in preschool children, demonstrating lack of efficacy for primary asthma-like symptom prevention in this population.

Clinical Trial Data

Phase

Primary Endpoint

Not Met

Outcome Details

Oral administration of OM-85 did not decrease the incidence of wheezing lower respiratory tract illness in the high-risk population studied

Importance:6/10

Sentiment:

-0.80

Phase 3 failurerespiratory diseasepediatricsprimary preventionbacterial lysateasthma

Read the original article

Published by The Lancet on September 7, 2026 10:30 PM

Read Original